Zealand: Very positive phase III data with dasiglucagon rescue pen for severe hypos (BUY, Fair Value DKK162 vs. DKK155 (+42%))
Zealand: (BUY, Fair Value DKK162 vs. DKK155 (+42%))Very positive phase III data with dasiglucagon rescue pen for severe hypos
Zealand is continuing to deliver on its roadmap and, after divesting lixisenatide rights last week, published very positive phase III data yesterday with dasiglucagon as rescue therapy in adults with severe hypoglycemic episodes. The drug showed a very fast onset of action and allowed full recovery of patients within 15 minutes while offering much greater convenience for those who have to administer the product in a situation of emergency. It therefore looks like a potential best-in-class product. Now, Zealand will move to the filing as quickly as possible to be as close as possible to competition while looking for a commercial partner, with a focus on the US market. We increase our PoS from 60% to 80% while keeping very conservative sales assumptions. We reiterate our BUY.
Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.